NLRP3 and synovial sarcoma: Vaccine adjuvants enhance vaccine immunogenicity by activating the NLRP3 inflammasome, a crucial immune system component linked to autoimmune diseases like ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus, SS, and systemic sclerosis [8,9].